Therapy Areas
Hackett Appointed Chairperson of AgeX Board of Directors
19 May 2022 - - Dr. Joanne Hackett has been appointed chairperson of US-based biotechnology company AgeX Therapeutics, Inc's (NYSE American: AGE) board of directors, the company said.

Dr. Hackett joined the board of directors in December 2021. She will serve in a non-executive capacity as AgeX's chairperson.

Dr. Greg Bailey, who served as AgeX's chairperson since 2018, will continue to serve as a member of AgeX's board of directors.

Dr. Hackett is the Head of Genomic and Precision Medicine at Iqvia, a world leader in using data, technology, advanced analytics, and expertise to help customers drive healthcare forward.

From 2017 to 2020, Dr. Hackett served as chief commercial officer of Genomics England, owned by the Department of Health and Social Care in the United Kingdom.

During 2016 and 2017, Dr. Hackett served as chief commercial officer and Interim chief executive officer of the Precision Medicine Catapult, which was established in the United Kingdom with the goal of developing and commercializing precision medicine.

Dr. Hackett holds a PhD in Molecular Genetics from the University of New Brunswick.

AgeX Therapeutics, Inc. (NYSE American: AGE) is focused on developing and commercializing innovative therapeutics to treat human diseases to increase healthspan and combat the effects of aging.

AgeX's PureStem and UniverCyte manufacturing and immunotolerance technologies are designed to work together to generate highly defined, universal, allogeneic, off-the-shelf pluripotent stem cell-derived young cells of any type for application in a variety of diseases with a high unmet medical need.

AgeX has two preclinical cell therapy programs: AGEX-VASC1 (vascular progenitor cells) for tissue ischemia and AGEX-BAT1 (brown fat cells) for Type II diabetes.

AgeX's revolutionary longevity platform induced Tissue Regeneration aims to unlock cellular immortality and regenerative capacity to reverse age-related changes within tissues.

HyStem is AgeX's delivery technology to stably engraft PureStem or other cell therapies in the body.

AgeX is seeking opportunities to establish licensing and collaboration arrangements around its broad IP estate and proprietary technology platforms and therapy product candidates.